

Executive Summary: Central Banks in Focus

Stronger-than-expected US GDP data cheer the markets, demonstrating that recession prospects have become a major worry for investors. In 4Q22, the US GDP grew by 2.9% y/y (vs 2.6% consensus forecast and down from previous quarter's 3.2%). In addition, the durable goods orders* grew by stunning 5.6% m/m in December (vs 2.5% forecast and up from November's -1.7%). These strong activity data prints produced a positive sentiment in the market, leading to a 2.5% weekly rally in S&P 500 as well as significant gains in most global equity indices.

An important observation has to be made here. Throughout 2022, positive economic news mostly implied negative price movements in the markets, as they foreshadowed more hawkish Fed in a near future. In contrast, in 2023, markets had positive reaction to the latest macroeconomic releases, which demonstrates that it is recession odds that investors now fear the most. This is another reminder that despite a strong start to the year, downside risks to Western economies remain elevated and could potentially translate into short-to-medium term market losses.

This week is expected to be highly volatile, with major central banks making interest rate decisions and many of the largest US companies reporting earnings. The FOMC meeting will take place on Wednesday, with the US Federal Reserve expected to slow the hiking pace to 25bps, reaching the base rate range of 4.75%-5.0%. Importantly, it is highly possible that the monetary policy decision will be accompanied by a hawkish speech, as to compensate for smaller sized rate hike. The recent stronger-than-expected US GDP data underlies this view. Meanwhile, Bank of England (BoE) and European Central Bank (ECB) will meet on Thursday, both expected to hike by 50 bps, reaching the policy rates of 4.0% and 3.0%, respectively. Lastly, some of the most renowned US companies will be reporting their quarterly results, including Apple, Meta Platforms, Alphabet, Amazon.com, and AMD.

*Note: Durable goods orders is one of the most closely watched macroeconomic statistics, as it closely portrays producers' expectations on mid-term demand in the economy.

Eva Bochorishvili - Head of Research |evabochorishvili@gt.ge| +995 32 2401 111 ext. 8036

Bachana Shengelia - Head of Sector Research |bshengelia@gt.ge| +995 32 2401 111 ext. 7562

Giorgi Tskitishvili - Equity Markets Analyst |g.tskitishvili@gt.ge| +995 32 2401 111 ext. 7562

Performance of major equity indices

Index	W/W, %	M/M, %	YTD, %
S&P 500	2.5	6.3	6.0
NASDAQ	4.3	12.3	11.0
Dow Jones	1.8	2.2	2.5
Russsell 2000	2.4	9.3	8.5
FTSE 100 (£)	-0.2	4.2	2.8
FTSE 250 (£)	1.7	6.4	6.3
STOXX 600 (€)	0.7	6.3	7.1
Nikkei 225 (¥)	3.1	3.5	4.9
MSCI China	2.5	18.0	14.2
MSCI EAFE	0.8	9.1	8.1
MSCI EM	1.4	9.6	9.9
MSCI World	4.5	10.5	11.2
Source: Bloomberg			

Note: All data is denominated in USD unless specified otherwise

Major US equity indices





Source: Bloomberg



Weekly sector performance highlights

Consumer discretionary was the top performing sector last week, with the associated ETF up 6.4% w/w. The main driver of rally was a 33.3% surge in Tesla stock, the second largest company from consumer discretionary sector. Out of remaining 15 largest companies, top performers were General Motors (GM 7.4%), Ford Motor Company (F, 7.0%), Amazon.com (AMZN, 5.1%), Booking Holdings (BKNG, 5.1%), Starbucks (SBUX, 3.8%), Marriott International (MAR, 4.5%), and Target (TGT, 3.9%). Modest growth was also observed in TJX Companies (TJX, 3.0%), Dollar General (DG, 2.4%), (MCD, 1.4%), Nike (NKE, 0.7%), and Home Depot (HD, 0.5%). Lastly, Lowe's Companies (LOW, -1.0%) and O'Reilly Automotive (ORLY, -2.8%) lost the ground.

Health Care was the worst performer, with respective ETF down 0.8%. All 12 largest health care companies closed the week in red, with the list of the largest losers including Merck & Co (MRK, - 4.2%), Pfizer (PFE, -2.9%), Thermo Fisher Scientific (TMO, -3.4%), Danaher (DHR, -3.1%), Amgen (AMGN, -3.6%). In contrast, the three smallest companies from the sector's top 15 gained the ground: Elevance (ELV, 2.7%), Medtronic (MDT, 2.1%), and Gilead Sciences (GILD, 0.9%).

Sector	ETF Ticker	Weekly ETF Change %	Close Price, \$	Market Cap, \$bn	P/E	YTD, %
S&P 500	SPY	2.5	405.7	380.3	21.8	6.1
of which:						
Cons. Discret.	XLY	6.4	147.9	14.5	22.3	14.5
Communication	XLC	4.1	55.3	9.4	18.9	15.2
Technology	XLK	4.1	136.7	41.0	27.2	9.9
Real Estate	XLRE	2.9	40.4	5.4	24.8	9.3
Financials	XLF	2.5	36.3	33.1	14.3	6.0
Industrials	XLI	2.2	101.1	13.6	20.5	3.0
Energy	XLE	0.8	91.2	42.8	7.5	4.3
Materials	XLB	0.7	83.4	6.2	10.0	7.4
Cons. Staples	XLP	0.3	72.9	17.0	24.4	-2.3
Utilities	XLU	-0.5	68.9	15.9	22.9	-2.3
Health Care	XLV	-0.8	132.9	40.8	24.5	-2.2

S&P 500 sector review: last week performance

Source: Bloomberg, Capital IQ



Performance of last week's most traded stocks globally (top 20 by value)

#	Ticker	Name	Close Price, \$	W/W, %	YTD, %	P/E	12M Price Target, \$	12M Return Target, %
1	TSLA	Tesla	177.9	33.3	44.4	45.1	193.5	8.8
2	NVDA	NVIDIA	203.7	14.2	39.4	52.6	210.5	3.4
3	АХР	American Express	172.3	13.7	16.6	15.8	163.3	-5.2
4	ΜΕΤΑ	Meta Platforms	151.7	8.9	26.1	21.0	158.8	4.7
5	CRM	Salesforce	164.5	8.8	24.1	29.4	191.5	16.4
6	AMD	Advanced Micro Devices	75.4	7.6	16.4	24.1	85.1	12.9
7	DIS	Walt Disney	109.5	5.9	26.1	26.4	120.9	10.4
8	AAPL	Apple	145.9	5.8	12.3	23.8	172.8	18.4
9	NFLX	Netflix	360.8	5.3	22.3	31.6	346.0	-4.1
10	AMZN	Amazon.com	102.2	5.1	21.7	77.2	134.3	31.4
11	AVGO	Broadcom Inc	591.0	3.5	5.7	14.5	660.8	11.8
12	MSFT	Microsoft	248.2	3.3	3.5	25.1	270.8	9.1
13	v	Visa	231.4	3.2	11.4	26.7	258.1	11.5
14	ВА	The Boeing Company	211.2	2.1	10.9	N/A	240.5	13.9
15	ХОМ	Exxon Mobil	115.6	2.0	4.8	9.9	124.2	7.4
16	GOOGL	Alphabet	99.4	1.4	12.6	20.4	128.0	28.8
17	UNH	UnitedHealth Group	486.1	-0.1	-8.3	19.5	605.4	24.6
18	CVX	Chevron	179.5	-0.8	0.0	11.5	194.5	8.4
19	SCHW	Charles Schwab	74.7	-3.0	-10.3	16.5	93.3	24.9
20	INTC	Intel	28.2	-3.6	6.5	56.1	27.3	-3.1

Source: Bloomberg, Capital IQ

Note: Positive 12 month return targets imply an overall "Buy" recommendation by analysts



Week ahead calendar

Key macro	econo	mic re	ieases

Key	company	earnings
-----	---------	----------

	Time (GMT +4)	Country	Event	Company	Ticker	Time	Forecast EPS \$
Monday January 30	12:00	Germany	GDP prel. (4Q22)	Ryanair	RYAAY	Premarket	1.13
	14:00	Europe	Consumer Confidence (Jan)	NXP	NXPI	After market	3.64
	14:00	Europe	Economic Sentiment (Jan)	Principal Financial	PFG	After market	1.54
	05:30	China	Manufacturing PMI (Jan)	Exxon Mobil	ХОМ	Premarket	3.29
	11:45	France	Inflation prel. (Jan)	Pfizer	PFE	Premarket	1.07
sday ary 31	12:55	Germany	Employment (Jan)	McDonald's	MCD	Premarket	2.45
Tuesday January 31	14:00	Europe	GDP prel. (4Q22)	United Parcel Service	UPS	Premarket	3.59
	17:00	Germany	Inflation prel. (Jan)	Amgen	AMGN	After market	4.09
	19:00	US	Consumer Confidence	AMD	AMD	After market	0.67
	13:00	Europe	Manufacturing PMIs (Jan)	Novo Nordisk	NVO	Premarket	0.83
esday ary 1	14:00	Europe	Inflation (Jan)	Thermo Fisher Scientific	тмо	Premarket	5.22
Wednesday February 1	19:00	US	Manufacturing PMI (Jan)	Meta Platforms	META	After market	2.26
	23:00	US	Fed Interest Rate Decision	Alibaba	BABA	N/A	16.63
	16:00	UK	BoE Interest Rate Decision	Eli Lilly	LLY	Premarket	1.80
sday Jary 2	17:15	Europe	ECB Interest Rate Decision	Apple	AAPL	After market	1.94
Thurs Februa	19:00	US	Factory Orders (Dec)	Alphabet	GOOGL	After market	1.18
				Amazon.com	AMZN	After market	0.17
~	13:00	Europe	Services PMIs (Jan)	Cigna	CI	Premarket	4.87
Friday February 3	17:00	US	Employment (Payrolls) (Jan)	Regeneron Pharma	REGN	Premarket	10.2
Feb F	19:00	US	Services PMI (Jan)	Aon	AON	Premarket	3.67

Source: Bloomberg, Financial Times



Disclaimer

This document is the property of and has been prepared by JSC Galt & Taggart ("Galt & Taggart"), a member of Bank of Georgia group PLC ('Group") solely for informational purposes and independently of the respective companies mentioned herein. This document does not constitute or form part of, and should not be construed as, an offer or solicitation or invitation of an offer to buy, sell or subscribe for any securities or assets and nothing contained herein shall form the basis of any contract or commitment whatsoever or shall be considered as a recommendation to take any such actions.

Galt & Taggart is authorized to perform professional activities on the Georgian market. The distribution of this document in certain jurisdictions may be restricted by law. Persons into whose possession this document comes are required by Galt & Taggart to inform themselves about and to observe any and all restrictions applicable to them. This document is not directed to, or intended for distribution, directly or indirectly, to, or use by, any person or entity that is a citizen or resident located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

Investments (or any short-term transactions) in emerging markets involve significant risk and volatility and may not be suitable for everyone. The recipients of this document must make their own investment decisions as they believe appropriate based on their specific objectives and financial situation. When doing so, such recipients should be sure to make their own assessment of the risks inherent in emerging market investments, including potential political and economic instability, other political risks including without limitation changes to laws and tariffs, and nationalization of assets, and currency exchange risk.

No representation, warranty or undertaking, express or implied, is or will be made by Galt & Taggart or any other member of the Group or their respective directors, employees, affiliates, advisers or agents or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this document and the information contained herein (and whether any information has been omitted from this document) and no reliance should be placed on it. This document should not be considered as a complete description of the markets, industries and/or companies referred to herein. Nothing contained in this document is, is to be construed as, or shall be relied on as legal, investment, business or tax advice, whether relating to the past or the future, by Galt & Taggart any other member of the Group or any of their respective directors, employees, affiliates, advisers or agents in any respect. Recipients are required to make their own independent investigation and appraisal of the matters discussed herein. Any investment decision should be made at the investor's sole discretion. To the extent permitted by law, Galt & Taggart, any other member of the Group or any loss or damages however arising, directly or indirectly, from any use of this document or its contents or otherwise arising in connection with this document, or for any act, or failure to act, by any party, on the basis of this document.

The information in this document is subject to verification, completion and change without notice and Galt & Taggart is not under any obligation to update or keep current the information contained herein. The delivery of this document shall not, under any circumstances, create any implication that there has been no change in the information since the date hereof or the date upon which this document has been most recently updated, or that the information contained in this document is correct as at any time subsequent to the date on which it is supplied or, if different, the date indicated in the document containing the same. No representation or warranty, expressed or implied, is made by Galt & Taggart or any other member of the Group, or any of their respective directors, employees, affiliates, advisers or agents with respect to the accuracy or completeness of such information.

The information provided and opinions expressed in this document are based on the information available as of the issue date and are solely those of Galt & Taggart as part of its internal research coverage. Opinions, forecasts and estimates contained herein are based on information obtained from third party sources believed to be reliable and in good faith, and may change without notice. Third party publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. Accordingly, undue reliance should not be placed on any such data contained in this document. Neither Galt & Taggart, any other member of the Group, nor their respective directors, employees, affiliates, advisors or agents make any representation or warranty, express or implied, of this document's usefulness in predicting the future performance, or in estimating the current or future value, of any security or asset.

Galt & Taggart does, and seeks to do, and any other member of the Group may or seek to do business with companies covered in its research. As a result, investors should be aware of a potential conflict of interest that may affect the objectivity of the information contained in this document.

Unauthorized copying, distribution, publication or retransmission of all or any part of this document by any medium or in any form for any purpose is strictly prohibited.

The recipients of this document are responsible for protecting against viruses and other destructive items. Receipt of the electronic transmission is at risk of the recipient and it is his/her responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature.

Galt & Taggart Address: 3 A. Pushkin Street, Tbilisi 0105, Georgia Tel: + (995) 32 2401 111 Email: research@gt.ge